araag2/HINT huggingface dataset:
Clinical trial NCT01342211 (phase 2, status: completed)
Conditions: hypercholesterolemia, dyslipidemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: statin, statin, statin, satin, statin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  On a stable daily dose of atorvastatin, rosuvastatin or simvastatin.

          -  Lipids meet the following criteria at screening and prior to dosing: Fasting LDL-C
             greater than 100 mg/dL and fasting TG less than 400 mg/dL

        Exclusion Criteria:

          -  History of a cardiovascular or cerebrovascular event or procedure during the past
             year.

          -  Poorly controlled type 1 or type 2 diabetes mellitus.

          -  Poorly controlled hypertension.
Clinical trial NCT00476554 (phase 2, status: terminated)
Conditions: cutaneous t-cell lymphoma (ctcl)
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: sapacitabine
SMILES: CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1C#N
Reason stopped: 
    slow accrual and financial resource limitation
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients with advanced CTCL

          -  Have had at least 2 systemic therapies

          -  Must have evaluable disease

          -  Eastern Cooperative Oncology Group performance status 0-2

          -  Adequate bone marrow, hepatic and renal function

          -  At least 3 weeks from prior therapies

          -  Not receiving topical steroids or have been on a stable dose of topical steroids for
             at least 2 weeks

          -  Able to swallow capsules

          -  At least 3 weeks from major surgery

          -  Agree to practice effective contraception

          -  Able to understand and willing to sign the informed consent form

        Exclusion Criteria:

          -  Receiving systemic steroids

          -  Receiving topical or systemic retinoids or vitamin A

          -  Receiving radiotherapy, biological therapy,or any other investigational agents

          -  Uncontrolled intercurrent illness

          -  Pregnant or lactating women

          -  Known to be HIV-positive

          -  Active hepatitis B and/or hepatitis C infection
Clinical trial NCT01349803 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: pt005 mdi, pt001 mdi, pt003 mdi, formoterol fumarate 12 μg (foradil® aerolizer®)
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70

          -  A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

          -  Acceptable baseline (Visit 2) Holter monitor recording

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

          -  Clinically significant abnormal findings during the baseline Holter recording

          -  Patients with a pacemaker or ICD/CRT/CRT_D devices

        Other inclusion/exclusion criteria as defined by the protocol
Clinical trial NCT00106639 (phase 2, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: cp-690,550, cp-690,550, tacrolimus
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Recipient of a first-time kidney transplant

          -  Between the ages of 18 and 70 years, inclusive

        Exclusion Criteria:

          -  Recipient of any non-kidney transplant
Clinical trial NCT00338884 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sunitinib malate
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced kidney cancer

        Exclusion Criteria:

          -  Previous treatment for kidney cancer, except surgical removal of kidney tumor
Clinical trial NCT00566267 (phase 2/phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: simvastatin 20 mg/ezetimibe
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Moderately obese with hyperlipidemia

        Exclusion Criteria:

          -  Recent unstable heart or lung condition

          -  Current use of other lipid modifying drugs

          -  Hepatic disease

          -  Pregnancy or lactation
Clinical trial NCT01125774 (phase 2/phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: telcagepant, placebo
SMILES: [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant who has had regular menstrual cycles monthly (22 to 32 days) for at least
             the last 3 cycles

          -  Participant experiences headache during menstrual period in at least 2 out of last 3
             cycles

          -  Participant has history of migraine for ≥ 3 months and with ≥ 2 migraine attacks per
             month in the 2 months prior to screening

          -  Participant agrees to use an effective method of birth control through the duration of
             the study

        Exclusion Criteria:

          -  Participant has basilar or hemiplegic migraine headache

          -  Participant has taken medication for acute headache on more than 15 days per month in
             the 3 months prior to screening

          -  Participant is taking prophylactic medication for migraine and daily dose has changed
             within 4 weeks prior to screening

          -  Participant has history of significant liver disease

          -  Participant has had cardiac surgery or symptoms within 3 months of screening

          -  Participant has confounding pain syndromes, psychiatric conditions, dementia, or major
             neurological disorders other than migraine

          -  Participant has history of neoplastic disease ≤ 5 years prior to signing informed
             consent

          -  Participant has history of gastric or small intestinal surgery

          -  Participant consumes 3 or more alcoholic drinks per day
Clinical trial NCT00262730 (phase 2, status: completed)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: poly iclc, temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)
             by biopsy or resection within the past 3 months

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status ≥ 60%

          -  Absolute neutrophil count ≥ 1500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Bilirubin ≤ 1.5 mg/dL

          -  Transaminases ≤ 4 times above the upper limits of the institutional normal

          -  Creatinine ≤ 1.7 mg/dL

          -  Not pregnant or breast-feeding

          -  Patients must agree to follow acceptable birth control methods to avoid conception

          -  Negative pregnancy test

          -  Patients must have a Mini Mental State Exam score of ≥ 15

          -  No serious concurrent infection or medical illness which would jeopardize the ability
             of the patient to receive the treatment outlined in this protocol with reasonable
             safety

          -  Patients with a concurrent or prior malignancy are ineligible unless they are patients
             with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin

               -  Patients who have been free of disease (any prior malignancy) for ≥ five years
                  are eligible for this study

          -  Patients requiring ongoing therapy for psychoses with antipsychotic medications at the
             time of enrollment will be ineligible

        PRIOR CONCURRENT THERAPY:

          -  Patients must not have received prior radiation therapy, chemotherapy, immunotherapy
             or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense,
             peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or
             hormonal therapy for their brain tumor

               -  Prior glucocorticoid therapy is allowed

          -  Patients must be willing to forego other cytotoxic and non-cytotoxic drug therapy
             against the tumor while being treated with poly ICLC plus temozolomide on this
             protocol

          -  No other concurrent therapy for their tumor (i.e., chemotherapeutics or
             investigational agents)

          -  Patients who have received prior Gliadel wafers are not eligible for this study

          -  No concurrent prophylactic filgrastim (G-CSF)

          -  No concurrent electron, particle, implant, or stereotactic radiosurgery boost
Clinical trial NCT00475657 (phase 2, status: terminated)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    terminated due to lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of Small Cell Lung Cancer (SCLC).

          -  Functional stage from 0 to 2 of the ECOG functional scale

          -  No previous systemic chemotherapy, immunotherapy or biologic therapy for SCLC.

          -  Previous bone marrow radiotherapy less than 25% is allowed.

          -  There must be at least one measurable lesion that complies with the solid tumor
             response evaluation criteria.

          -  Appropriate organic function.

          -  Life expectancy estimated at 12 weeks minimum.

          -  Females must be surgically sterile, postmenopausal or follow approved medical
             contraceptive methods during the treatment period and 6 months afterwards. Males must
             be surgically sterile or use a contraceptive method during the treatment period and
             during 6 months after treatment.

          -  The patient must be compliant and located close to the trial area for appropriate
             follow-up.

          -  The patient or his/her legal representative must sign an informed consent document.

          -  Patients must be at least 18 years of age.

        Exclusion Criteria:

          -  Having received treatment for the last 30 days with a drug that has not obtained
             regulatory approval.

          -  Having participated in a previous pemetrexed trial.

          -  Mixed histologic diagnosis of SCLC and NSCLC.

          -  Concurrent illness.

          -  Having an active infection.

          -  Severe cardiac disease.

          -  Having received recently or concurrently a vaccine against yellow fever.

          -  Having suffered a previous malignant process other than SCLC.

          -  Central nervous system (CNS) metastases require concurrent corticoid therapy. Treated
             and stable CNS metastases are allowed.

          -  Clinically relevant fluid accumulation in the third space.

          -  Significant weight loss (greater than or equal to 10%) within 6 weeks prior to trial
             inclusion.

          -  Concurrent administration of any other anti-tumor treatment.

          -  Severe renal failure.

          -  Unable to discontinue administration of non-steroidal anti-inflammatory (NSAIDS)
             agents.

          -  Inability or unwillingness to take folic acid and vitamin B12 supplements.

          -  Inability to take corticoids.
Clinical trial NCT01376557 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: 75 mg lx4211, 200 mg lx4211, 400 mg lx4211, 200 mg lx4211, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult subjects between the ages of 18 to 75 years, inclusive

          -  Confirmed diagnosis of Type 2 diabetes mellitus

          -  Meet required laboratory values at screening, including fasting plasma glucose less
             than 270 mg/dL

          -  Stable dose of metformin monotherapy greater than 1500 mg/day for at least 8 weeks

          -  Willing and able to provide written informed consent

          -  Willing and able to maintain consistent dietary, physical activity, and sleeping
             patterns throughout the study

        Exclusion Criteria:

          -  History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic
             syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes

          -  History of renal disease or clinically significant abnormal kidney function tests

          -  Presence of active hepatic disease or clinically significant abnormal liver function
             tests

          -  Subjects with a history of heart attack, severe/unstable angina, or coronary
             revascularization procedure within 6 months prior to study Day 1

          -  History of clinically significant cardiac arrhythmias within one year of study Day 1

          -  Subjects with congestive heart failure

          -  Subjects with uncontrolled Stage III hypertension

          -  Triglycerides >1000 mg/dL at Screening

          -  Known history of HIV or hepatitis C

          -  History of illicit drug or alcohol abuse with one year of study Day 1

          -  Have had 2 or more emergency room visits, doctor visits, or hospitalizations due to
             hypoglycemia within 6 months of study Day 1

          -  Use of any other investigational drug within 30 days of study Day 1

          -  Prior exposure to LX4211

          -  Use of any medication or herbal supplement for the purpose of weight loss

          -  Chronic use of any antidiabetic therapy other than metformin in the 3 months prior to
             study Day 1

          -  Use of corticosteroids within 2 weeks prior to study Day 1

          -  Major surgery within 6 months of study Day 1

          -  Subjects with any history of severe gastroparesis

          -  Inability or difficulty swallowing whole capsules or tablets

          -  Women who are pregnant or breast feeding
Clinical trial NCT00560209 (phase 2, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: ono-1101, ono-1101, ono-1101
SMILES: CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1, CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1, CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1
Eligibility criteria:

        Inclusion Criteria:

          -  20 years of age or older

          -  Heart rate less than 90 beats/min and more than 70 beats/min at entering the CT room

        Exclusion Criteria:

          -  Previous allergic reactions to contrast agent

          -  Renal failure

          -  Asthma

          -  Concomitant beta-receptor blocking agent
Clinical trial NCT00225056 (phase 2, status: terminated)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel and capecitabine
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Reason stopped: 
    terminated due to lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  must have metastatic breast cancer

          -  must have cytologically or pathologically confirmed invasive ductal or lobular
             carcinoma

          -  must have measurable or evaluable disease

          -  ECOG of 0-1

          -  patients may have received 0, 1. or 2 prior treatments for metastatic breast cancer

          -  must have adequate organ function

          -  must be at least 19 years of age

          -  peripheral neuropathy less than or equal to grade 1

          -  must have voluntarily signed informed consent

          -  patients with brain metastases are eligible provided that other measurable disease
             exists and brain lesions are controlled

        Exclusion Criteria:

          -  patients with other malignancies, except non melanoma of the skin, who have had any
             evidence of cancer within the last 5 years

          -  patients with psychiatric illness or other concurrent severe co-morbid medical
             condition that would preclude study completion

          -  known uncontrolled existing coagulopathy

          -  patients with a history of severe hypersensitivity reaction to docetaxel, medications
             formulated with polysorbate 80 or 5-fluorouracil

          -  use of other investigational agents in the last 28 days

          -  pregnant or lactating women

          -  patients who are known HIV positive

          -  patients with life expectancy of less than 3 months

          -  sexually active patients unwilling to practice reliable contraception during the study
Clinical trial NCT01441635 (phase 2, status: completed)
Conditions: heavy uterine bleeding, uterine fibroids
ICD codes: N92.3, N95.0, K29.80, K29.81, I85.00, I85.01, K20.80
Drugs: elagolix, placebo, estradiol/norethindrone acetate (e2/neta), estradiol, progesterone
SMILES: COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is a pre-menopausal female 20 to 49 years of age.

          -  Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound assessed
             by a central reader and verification that a fibroid present met the following
             criteria:

               -  At least 1 fibroid with diameter ≥ 2 cm (longest diameter), or multiple small
                  fibroids with a total uterine volume of ≥ 200 cm³ to ≤ 2,500 cm³ (approximately
                  22 weeks' gestation) as documented by a centrally read ultrasound.

               -  Only intramural, submucosal non-pedunculated, and subserosal fibroids qualified
                  subjects for enrollment (intracavitary pedunculated fibroids were exclusionary).

               -  Ultrasound procedures were performed during the Screening Period, and subjects
                  were not randomized until the investigator reviewed the central reader results
                  verifying the inclusion requirements.

          -  Subject has a history of regular menstrual cycles between 24 to 35 days.

          -  Subject has heavy uterine bleeding associated with uterine fibroids as evidenced by
             blood loss > 80 mL during 2 screening menstrual cycles, measured by the alkaline
             hematin method.

        Exclusion Criteria:

          -  Subject has had a myomectomy, uterine artery embolization, or high intensity focused
             ultrasound for fibroid destruction within 1 year prior to randomization or any history
             of endometrial ablation.

          -  Subject has a history of osteoporosis or other metabolic bone disease.

          -  Subject shows evidence of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including
             depression), or neurologic diseases or any uncontrolled medical illness such as
             uncontrolled type 2 diabetes.

          -  Subject has a history of clinically significant condition(s) including but not limited
             to:

               -  Endometriosis

               -  Epilepsy or seizures

               -  Type 1 diabetes

               -  Any cancer (except basal cell carcinoma of the skin), including breast or ovarian
                  cancer or subject has taken any systemic cancer chemotherapy